News
- Author:
- Jim Kling
Publish date: July 22, 2022
While tyrosine kinase inhibitors were found to be associated with more serious adverse events, both treatments had similar toxic effects.
News
- Author:
- Jim Kling
Publish date: July 22, 2022
Phase 2 trial offers hope of a chemotherapy-free option for patients with advanced NSCLC.
News
- Author:
- Jim Kling
Publish date: July 18, 2022
Studies find encouraging trends of stage shifting and minority screening, but more work remains.
News
- Author:
- Jim Kling
Publish date: July 14, 2022
“Until we can further define who the highest-risk patients are, I think it’s hard to give it to everyone,” one doctor says.
News
- Author:
- Jim Kling
Publish date: July 13, 2022
One out of three lung cancer patients previously treated with chemotherapy and immune therapy responded to a new targeted therapy.
News
- Author:
- Jim Kling
Publish date: July 12, 2022
Previous studies have examined worldwide BTC incidence; few looked at multiple global regions or at all subtypes.
News
- Author:
- Jim Kling
Publish date: July 11, 2022
Persistent viral antigens could be behind multiorgan symptoms: The majority of patients with gut antigen persistence had symptoms of postacute COVI...
News
- Author:
- Jim Kling
Publish date: July 5, 2022
These rare conditions have separate genetic mutations but can share symptoms; new evidence suggests the two mutated proteins work together.
News
- Author:
- Jim Kling
Publish date: June 30, 2022
A dramatic increase in therapy options prompted the first guidance issued by ASCO earlier this year.
News
- Author:
- Jim Kling
Publish date: June 30, 2022
A phase 2 trial found high response rates in patients classified as favorable risk and more widespread PD-L1 expression.
News
- Author:
- Jim Kling
Publish date: June 28, 2022
“This is very encouraging data and represents the real-world effectiveness of these therapies.”
News
- Author:
- Jim Kling
Publish date: June 24, 2022
An emphasis on nonpharmacologic approaches, such as diet and psychological interventions, can sometimes handle even less familiar sources of pain.<...
News
- Author:
- Jim Kling
Publish date: June 22, 2022
The drug showed benefit in PPI refractory symptoms for patients with non-acid reflux.
News
- Author:
- Jim Kling
Publish date: June 22, 2022
Rural and underserved areas may lack the technology needed to access innovative care solutions.
News
- Author:
- Jim Kling
Publish date: June 20, 2022
Lobular cancers differ physiologically, but trial results generally apply to ductal tumors.
